Study of avalglucosidase alfa use during pregnancy
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study collects safety information about avalglucosidase alfa when it’s taken during pregnancy and/or while breastfeeding. If you (or your baby) were exposed to this medicine and consent to be in a pregnancy safety registry, your information may help researchers better understand risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were exposed to avalglucosidase alfa during pregnancy and/or breastfeeding (lactation).
- Your situation involves either you or your baby being included in a safety report/registry process.
- Either an Individual Case Safety Report (ICSR) was already submitted to the sponsor for your exposure, or you can sign informed consent to join.
- You (the pregnant person) must be able to provide informed consent to enroll in the pregnancy sub-registry (if that path applies).
- The study has no stated exclusion rules, so eligibility mainly depends on exposure and consent/registration status.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a registry study that collects information over time from people with Pompe disease. It helps doctors and researchers better understand the condition and how it affects daily life, without testing any new treatments.
This study follows women with Fabry disease who took the medicine Elfabrio during pregnancy or breastfeeding to see if it is safe for them and their babies. It helps doctors learn more about how this treatment affects mothers and infants.
This study tests an experimental drug (S-606001) for people with late-onset Pompe disease. It aims to see if the drug can improve breathing and walking ability. You cannot have had enzyme replacement therapy for at least 3 months before joining.
This study is a follow-up for people with late-onset Pompe disease who have already completed a previous study of the investigational drug S-606001. It aims to continue monitoring safety and how well the treatment works over time.
This study follows people with Pompe disease over time and checks their “CRIM status,” which is a lab result about a key protein. It may help researchers better understand the disease and how it progresses for different patient groups.
This study follows pregnant and breastfeeding women with Fabry disease (and their infants) to better understand what happens during pregnancy and early life. You may or may not be taking migalastat, and the goal is to gather real-world information that could help future care.
Hear when a new Pompe Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.